Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 5 (2008), Issue 10 (October)

1. Sirtuins--novel therapeutic targets to treat age-associated diseases.
   Nat Rev Drug Discov, 7(10): 841-53. [Abstract] [Full-text]
2. The IL-33/ST2 pathway: therapeutic target and novel biomarker.
   Nat Rev Drug Discov, 7(10): 827-40. [Abstract] [Full-text]
3. Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy.
   Proc Natl Acad Sci U S A, 105(39): 14773-8. [Abstract] [Full-text]
4. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.
   J Natl Cancer Inst, 100(19): 1361-7. [Abstract] [Full-text]
5. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
   Br J Cancer, 99(7): 1050-5. [Abstract] [Full-text]
6. Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial.
   Br J Cancer, 99(7): 1020-6. [Abstract] [Full-text]
7. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.
   Am J Hematol, 83(10): 771-7. [Abstract] [Full-text]
8. Venous sinus thrombosis leading to stroke in a patient with sickle cell disease on hydroxyurea and high hemoglobin levels: treatment with thrombolysis.
   Am J Hematol, 83(10): 818-20. [Abstract] [Full-text]
9. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation.
   Obstet Gynecol, 112(4): 782-7. [Abstract] [Full-text]
10. Comparison of the in vitro and in vivo effects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma.
    Cancer Chemother Pharmacol, 63(1): 167-74. [Abstract] [Full-text]
11. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
    Cancer Chemother Pharmacol, 63(1): 181-8. [Abstract] [Full-text]
12. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
    Cancer Chemother Pharmacol, 63(1): 9-17. [Abstract] [Full-text]
13. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
    Cancer Chemother Pharmacol, 63(1): 99-107. [Abstract] [Full-text]
14. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
    Cancer Chemother Pharmacol, 63(1): 109-15. [Abstract] [Full-text]
15. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.
    Cancer Chemother Pharmacol, 63(1): 65-74. [Abstract] [Full-text]
16. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Cancer Chemother Pharmacol, 63(1): 85-9. [Abstract] [Full-text]
17. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
    Cancer Chemother Pharmacol, 63(1): 19-26. [Abstract] [Full-text]
18. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
    Cancer Chemother Pharmacol, 63(1): 1-8. [Abstract] [Full-text]
19. Retrospective evaluation of a computerized physician order entry adaptation to prevent prescribing errors in a pediatric emergency department.
    Pediatrics, 122(4): 782-7. [Abstract] [Full-text]
20. Free drug samples in the United States: characteristics of pediatric recipients and safety concerns.
    Pediatrics, 122(4): 736-42. [Abstract] [Full-text]
21. An intervention to decrease narcotic-related adverse drug events in children's hospitals.
    Pediatrics, 122(4): e861-6. [Abstract] [Full-text]
22. Cardiovascular risk screening before starting stimulant medications and prescribing practices of canadian physicians: impact of the Health Canada advisory.
    Pediatrics, 122(4): e828-34. [Abstract] [Full-text]
23. Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells.
    J Med Chem, 51(19): 5964-73. [Abstract] [Full-text]
24. Interactions of poly(amidoamine) dendrimers with Survanta lung surfactant: the importance of lipid domains.
    Langmuir, 24(19): 11003-8. [Abstract] [Full-text]
25. Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow.
    Pharm Res, 25(11): 2685-96. [Abstract] [Full-text]
26. Multifunctional polymeric micelles for enhanced intracellular delivery of doxorubicin to metastatic cancer cells.
    Pharm Res, 25(11): 2555-66. [Abstract] [Full-text]
27. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro.
    Pharm Res, 25(11): 2567-72. [Abstract] [Full-text]
28. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Am J Clin Oncol, 31(5): 476-80. [Abstract] [Full-text]
29. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Am J Clin Oncol, 31(5): 417-23. [Abstract] [Full-text]
30. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
    Am J Clin Oncol, 31(5): 413-6. [Abstract] [Full-text]
31. Effectiveness of vaccinating household contacts in addition to chemoprophylaxis after a case of meningococcal disease: a systematic review.
    Epidemiol Infect, 136(11): 1441-7. [Abstract] [Full-text]
32. Helios Gene Gun-mediated transfection of the inner ear sensory epithelium.
    Methods Mol Biol, 493: 103-23. [Abstract] [Full-text]
33. A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso.
    Malar J, 7: 180. [Abstract] [Full-text]
34. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.
    Blood, 112(8): 3122-5. [Abstract] [Full-text]
35. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
    Blood, 112(8): 3425-33. [Abstract] [Full-text]
36. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
    Blood, 112(8): 3107-14. [Abstract] [Full-text]
37. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
    Cancer, 113(8): 2139-45. [Abstract] [Full-text]
38. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
    Cancer, 113(8): 2020-8. [Abstract] [Full-text]
39. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
    Cancer, 113(8): 2038-45. [Abstract] [Full-text]
40. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Cancer, 113(8): 2110-8. [Abstract] [Full-text]
41. Clofarabine combinations as acute myeloid leukemia salvage therapy.
    Cancer, 113(8): 2090-6. [Abstract] [Full-text]
42. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
    Cancer, 113(8): 2046-52. [Abstract] [Full-text]
43. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
    Cancer, 113(8): 2097-101. [Abstract] [Full-text]
44. Accuracy of posterior subtalar joint injection without fluoroscopy.
    Clin Orthop Relat Res, 466(11): 2856-60. [Abstract] [Full-text]
45. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study).
    Jpn J Clin Oncol, 38(10): 715-8. [Abstract] [Full-text]
46. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Jpn J Clin Oncol, 38(10): 689-94. [Abstract] [Full-text]
47. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
    Jpn J Clin Oncol, 38(10): 675-82. [Abstract] [Full-text]
48. Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy.
    Cancer Lett, 271(2): 342-51. [Abstract] [Full-text]
49. Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
    J Antimicrob Chemother, 62(5): 866-71. [Abstract] [Full-text]
50. Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy.
    Arch Ophthalmol, 126(10): 1367-74. [Abstract] [Full-text]
51. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
    Circulation, 118(16): 1626-36. [Abstract] [Full-text]
52. Prevention of surgical site infection and appropriateness of antibiotic prescribing habits in plastic surgery.
    J Plast Reconstr Aesthet Surg, 61(11): 1347-56. [Abstract] [Full-text]
53. Everything old is new again? A fresh look at corticosteroids in ulcerative colitis.
    Am J Gastroenterol, 103(10): 2517-8. [Abstract] [Full-text]
54. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.
    Am J Gastroenterol, 103(10): 2509-16. [Abstract] [Full-text]
55. Structure of self-organized multilayer nanoparticles for drug delivery.
    Langmuir, 24(20): 11378-84. [Abstract] [Full-text]
56. Controlled rupture of magnetic polyelectrolyte microcapsules for drug delivery.
    Langmuir, 24(20): 11811-8. [Abstract] [Full-text]
57. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer.
    Br J Cancer, 99(8): 1232-8. [Abstract] [Full-text]
58. NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life.
    Br J Cancer, 99(8): 1226-31. [Abstract] [Full-text]
59. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
    Br J Cancer, 99(8): 1316-21. [Abstract] [Full-text]
60. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.
    Leukemia, 22(10): 1917-24. [Abstract] [Full-text]
61. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy.
    J Hypertens, 26(11): 2126-33. [Abstract] [Full-text]
62. Effects of age and gender on intravenous midazolam premedication: a randomized double-blind study.
    Br J Anaesth, 101(5): 632-9. [Abstract] [Full-text]
63. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
    Pediatr Blood Cancer, 51(6): 806-11. [Abstract] [Full-text]
64. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
    Pediatr Blood Cancer, 51(6): 747-53. [Abstract] [Full-text]
65. Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala.
    Pediatr Blood Cancer, 51(6): 760-4. [Abstract] [Full-text]
66. Lifetime hormonal factors may predict late-life depression in women.
    Int Psychogeriatr, 20(6): 1203-18. [Abstract] [Full-text]
67. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
    Gynecol Oncol, 111(1): 95-101. [Abstract] [Full-text]
68. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Gynecol Oncol, 111(1): 106-10. [Abstract] [Full-text]
69. Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Gynecol Oncol, 111(1): 27-34. [Abstract] [Full-text]
70. Ultrasound imaging of apoptosis in tumor response: novel preclinical monitoring of photodynamic therapy effects.
    Cancer Res, 68(20): 8590-6. [Abstract] [Full-text]
71. The controversial and short-lived early use of rehydration therapy for cholera.
    Clin Infect Dis, 47(10): 1315-9. [Abstract] [Full-text]
72. Preparation and characterization of silica xerogels as carriers for drugs.
    Drug Deliv, 15(8): 485-92. [Abstract] [Full-text]
73. Transport of surface engineered polyamidoamine (PAMAM) dendrimers across IPEC-J2 cell monolayers.
    Drug Deliv, 15(8): 515-22. [Abstract] [Full-text]
74. Polymeric nanoparticles for enhancing antiretroviral drug therapy.
    Drug Deliv, 15(8): 493-501. [Abstract] [Full-text]
75. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
    Urology, 72(4): 898-902. [Abstract] [Full-text]
76. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    J Clin Oncol, 26(30): 4928-33. [Abstract] [Full-text]
77. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    J Clin Oncol, 26(30): 4921-7. [Abstract] [Full-text]
78. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
    J Clin Oncol, 26(30): 4906-11. [Abstract] [Full-text]
79. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
    J Clin Oncol, 26(30): 4899-905. [Abstract] [Full-text]
80. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Ophthalmology, 115(10): 1756-65. [Abstract] [Full-text]
81. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial.
    Lancet, 372(9646): 1319-27. [Abstract] [Full-text]
82. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial.
    Lancet, 372(9646): 1310-8. [Abstract] [Full-text]
83. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Fertil Steril, 90(4): 1132-8. [Abstract] [Full-text]
84. A comparison of the efficacy, tolerability, and convenience of two formulations of follitropin-alpha in Iranian woman undergoing intracytoplasmic sperm injection cycles.
    Fertil Steril, 90(4): 1043-8. [Abstract] [Full-text]
85. Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome.
    Fertil Steril, 90(4): 1149-54. [Abstract] [Full-text]
86. Effect of oral estrogen on substrate utilization in postmenopausal women.
    Fertil Steril, 90(4): 1275-8. [Abstract] [Full-text]
87. Single injection peribulbar anesthesia with a short needle combined with digital compression.
    Anesth Analg, 107(5): 1751-3. [Abstract] [Full-text]
88. Murine endoglin-specific single-chain Fv fragments for the analysis of vascular targeting strategies in mice.
    J Immunol Methods, 339(1): 90-8. [Abstract] [Full-text]
89. Dual delivery of an angiogenic and an osteogenic growth factor for bone regeneration in a critical size defect model.
    Bone, 43(5): 931-40. [Abstract] [Full-text]
90. Predictors of in-hospital mortality for patients admitted with ST-elevation myocardial infarction: a real-world study using the Myocardial Infarction National Audit Project (MINAP) database.
    Heart, 94(11): 1407-12. [Abstract] [Full-text]
91. Primary venous aneurysms of the superficial venous system.
    Angiology, 59(5): 593-8. [Abstract] [Full-text]
92. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
    Nat Chem Biol, 4(11): 691-9. [Abstract] [Full-text]
93. Bioinformatic networks: molecular reticles for pinpointing pharmacological target selection.
    Clin Pharmacol Ther, 84(5): 543-5. [Abstract] [Full-text]
94. The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances.
    Toxicol Appl Pharmacol, 232(3): 487-97. [Abstract] [Full-text]
95. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins.
    Eur J Vasc Endovasc Surg, 36(5): 602-5. [Abstract] [Full-text]
96. Use of N-butyl cyanoacrylate in implantation of a port-catheter system for hepatic arterial infusion chemotherapy with the fixed-catheter-tip method: is it necessary?
    AJR Am J Roentgenol, 191(5): 1523-9. [Abstract] [Full-text]
97. Case report: Thromboembolic and septic complications of migrated cyanoacrylate injected for bleeding gastric varices.
    Br J Radiol, 81(971): e263-5. [Abstract] [Full-text]
98. Estrogen replacement therapy decreases plasma adiponectin but not resistin in postmenopausal women.
    Metabolism, 57(11): 1509-15. [Abstract] [Full-text]
99. Perioperative management of ventriculoperitoneal shunts during abdominal surgery.
    Surg Neurol, 70(5): 492-5; discussion 495-7. [Abstract] [Full-text]
100. Case report: spontaneous intracranial hypotension in association with the presence of a false localizing C1-C2 cerebrospinal fluid leak.
     Surg Neurol, 70(5): 539-43; discussion 543-4. [Abstract] [Full-text]
101. Lead hazards for pregnant women and children: part 2: more can still be done to reduce the chance of exposure to lead in at-risk populations.
     Am J Nurs, 108(11): 40-7; quiz 47-8. [Abstract] [Full-text]
102. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.
     BMC Cancer, 8: 295. [Abstract] [Full-text]
103. Network pharmacology: the next paradigm in drug discovery.
     Nat Chem Biol, 4(11): 682-90. [Abstract] [Full-text]
104. Targeting and tinkering with interaction networks.
     Nat Chem Biol, 4(11): 666-73. [Abstract] [Full-text]
105. Antiretroviral therapy prior to acute viral replication preserves CD4 T cells in the periphery but not in rectal mucosa during acute simian immunodeficiency virus infection.
     J Virol, 82(22): 11467-71. [Abstract] [Full-text]
106. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
     Ann Oncol, 19(11): 1882-7. [Abstract] [Full-text]
107. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
     Ann Oncol, 19(11): 1888-93. [Abstract] [Full-text]
108. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
     Ann Oncol, 19(11): 1860-9. [Abstract] [Full-text]
109. Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
     Ann Oncol, 19(11): 1903-9. [Abstract] [Full-text]
110. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
     Ann Oncol, 19(11): 1921-6. [Abstract] [Full-text]
111. Platinum-based chemotherapy in triple-negative breast cancer.
     Ann Oncol, 19(11): 1847-52. [Abstract] [Full-text]
112. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
     Ann Oncol, 19(11): 1837-41. [Abstract] [Full-text]
113. Antegrade continence enema in the treatment of congenital fecal incontinence beyond childhood.
     Dis Colon Rectum, 51(11): 1605-10. [Abstract] [Full-text]
114. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
     Pancreas, 37(4): 445-8. [Abstract] [Full-text]
115. Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial.
     Pancreas, 37(4): 366-70. [Abstract] [Full-text]
116. A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer.
     Jpn J Clin Oncol, 38(11): 748-54. [Abstract] [Full-text]
117. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
     Jpn J Clin Oncol, 38(11): 762-9. [Abstract] [Full-text]
118. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
     Cancer, 113(9): 2496-503. [Abstract] [Full-text]
119. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
     Cancer, 113(9): 2504-11. [Abstract] [Full-text]
120. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
     Cancer, 113(9): 2471-7. [Abstract] [Full-text]
121. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study.
     Cancer, 113(9): 2431-9. [Abstract] [Full-text]
122. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
     Cancer, 113(9): 2448-56. [Abstract] [Full-text]
123. Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1.
     Jpn J Clin Oncol, 38(11): 786-9. [Abstract] [Full-text]
124. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
     Cancer, 113(9): 2512-7. [Abstract] [Full-text]
125. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy.
     Cancer, 113(9): 2518-23. [Abstract] [Full-text]
126. A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer.
     Cancer, 113(9): 2532-8. [Abstract] [Full-text]
127. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
     Cancer Immunol Immunother, 58(1): 71-84. [Abstract] [Full-text]
128. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
     Cancer Immunol Immunother, 58(1): 111-20. [Abstract] [Full-text]
129. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.
     Cancer Immunol Immunother, 58(1): 49-59. [Abstract] [Full-text]
130. CT angiography-source image hypoattenuation predicts clinical outcome in posterior circulation strokes treated with intra-arterial therapy.
     Stroke, 39(11): 3107-9. [Abstract] [Full-text]
131. Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits.
     Stroke, 39(11): 3073-8. [Abstract] [Full-text]
132. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
     Eur J Surg Oncol, 34(11): 1231-6. [Abstract] [Full-text]
133. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
     Pediatr Infect Dis J, 27(11): 993-8. [Abstract] [Full-text]
134. Changes in Na+, K+ concentrations in perspiration and perspiration volume with alternating current iontophoresis in palmoplantar hyperhidrosis patients.
     Arch Dermatol Res, 300(10): 595-600. [Abstract] [Full-text]
135. A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells.
     Biotechnol Bioeng, 101(5): 1072-82. [Abstract] [Full-text]
136. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
     Int J Radiat Oncol Biol Phys, 72(4): 1154-60. [Abstract] [Full-text]
137. Incidence of soft tissue injury and neuropathy after embolo/sclerotherapy for congenital vascular malformation.
     J Vasc Surg, 48(5): 1286-91. [Abstract] [Full-text]
138. Off-label and unlicensed drug utilization in hospitalized children in Fortaleza, Brazil.
     Eur J Clin Pharmacol, 64(11): 1111-8. [Abstract] [Full-text]
139. Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time.
     Invest Ophthalmol Vis Sci, 49(11): 4808-15. [Abstract] [Full-text]
140. Medication reconciliation in a rural trauma population.
     Ann Emerg Med, 52(5): 483-91. [Abstract] [Full-text]
141. Photoreceptor protection after photodynamic therapy using dexamethasone in a rat model of choroidal neovascularization.
     Invest Ophthalmol Vis Sci, 49(11): 5008-14. [Abstract] [Full-text]
142. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
     Br J Cancer, 99(9): 1387-94. [Abstract] [Full-text]
143. Expression of squamous cell carcinoma antigen-1 in liver enhances the uptake of hepatitis B virus envelope-derived bio-nanocapsules in transgenic rats.
     FEBS J, 275(22): 5714-24. [Abstract] [Full-text]
144. Protoporphyrin IX nanoparticle carrier: preparation, optical properties, and singlet oxygen generation.
     Langmuir, 24(21): 12534-8. [Abstract] [Full-text]
145. Cationic and fluorescent "Janus" dendrimers.
     Org Lett, 10(21): 4751-4. [Abstract] [Full-text]
146. Human oocyte cryopreservation in infertility and oncology.
     Curr Opin Endocrinol Diabetes Obes, 15(6): 529-35. [Abstract] [Full-text]
147. Parathyroid hormone treatment for osteoporosis.
     Curr Opin Endocrinol Diabetes Obes, 15(6): 495-501. [Abstract] [Full-text]
148. The role of accurate testosterone testing in the treatment and management of male hypogonadism.
     Steroids, 73(13): 1305-10. [Abstract] [Full-text]
149. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
     J Clin Oncol, 26(31): 5052-9. [Abstract] [Full-text]
150. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
     J Clin Oncol, 26(31): 5043-51. [Abstract] [Full-text]
151. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
     J Clin Oncol, 26(31): 5027-35. [Abstract] [Full-text]
152. Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model.
     Cancer Res, 68(21): 9033-40. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.